Principal Financial Group Inc Vera Therapeutics, Inc. Transaction History

Principal Financial Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$33.72 - $48.82 $210,311 - $304,490	-6,237 Reduced 46.31%	7,230 $261,000
Q1 2024 Apr 29, 2024	BUY	$14.91 - $49.14 $2,191 - $7,223	147 Added 1.1%	13,467 $580,000
Q4 2023 Feb 07, 2024	SELL	$9.29 - $16.0 $4,189 - $7,216	-451 Reduced 3.27%	13,320 $204,000
Q3 2023 Nov 02, 2023	BUY	$13.71 - $19.64 $7,307 - $10,468	533 Added 4.03%	13,771 $188,000
Q2 2023 Aug 07, 2023	BUY	$6.11 - $17.83 $80,884 - $236,033	13,238 New	13,238 $212,000

184

55.1M

134K

156K

Ticker VERA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,042,300
Market Cap $1.15B
Description
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.